PTGS2 and breast carcinoma: Targeted therapies have been developed for suppressing the post-partum pro-tumorigenic extracellular matrix via inhibition of PTGS2 (O'Brien et al., 2011), and the potential benefit of targeting the FGF1 pathway in breast cancer has been considered (Francavilla and O’Brien, 2022).